Which of the following is true about treatment of CLL?
**Core Concept**
Chronic Lymphocytic Leukemia (CLL) is a type of cancer characterized by the progressive accumulation of mature, malignant lymphocytes in the bone marrow, lymphoid organs, and peripheral blood. The treatment of CLL involves a range of modalities, including chemotherapy, immunotherapy, targeted therapy, and stem cell transplantation.
**Why the Correct Answer is Right**
The treatment of CLL is typically guided by the patient's age, performance status, and disease stage. The correct answer is likely to be a treatment modality that has been shown to improve survival and quality of life in patients with CLL. For example, ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has been shown to improve progression-free survival and overall survival in patients with CLL. Another example is venetoclax, a BCL-2 inhibitor, which has been shown to induce durable responses in patients with CLL.
**Why Each Wrong Option is Incorrect**
**Option A:** This option may be incorrect because it is not a standard treatment for CLL.
**Option B:** This option may be incorrect because it is not a well-established treatment for CLL, or it may be a treatment that is used in specific cases but not as a first-line treatment.
**Option C:** This option may be incorrect because it is not a recommended treatment for CLL, or it may be a treatment that is associated with significant toxicity.
**Clinical Pearl / High-Yield Fact**
CLL is a heterogeneous disease, and treatment decisions should be individualized based on the patient's specific characteristics and disease features. The development of targeted therapies, such as ibrutinib and venetoclax, has significantly improved the treatment landscape for CLL.
**Correct Answer:** C.